A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia
This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.
Indication: Achondroplasia
Modality: combination therapy
Target: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Sponsor: Ascendis Pharma Growth Disorders A/S
Source URL: ClinicalTrials.gov
Source updated: Feb 18, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Target normalized: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections